title: mRNA splicing variants: exploiting modularity to outwit cancer therapy.
abstract: Systemic cancer therapy has traditionally exploited vulnerabilities in cancer cells, a strategy which has become more precise with the identification and targeting of driver oncogenes. However, persistent tumor growth due to primary (de novo) or secondary (acquired) resistance limits therapeutic efficacy for many patients. Alternative splicing is important for increasing the diversity of the cellular proteome, and is a process frequently deregulated during cancer development and progression. In cancer cells, diverse splicing alterations have been identified that eliminate protein domains or enzymatic activities required for efficacy of cancer therapies, promote gain of novel signaling functions that circumvent cancer therapies, and uncouple signaling pathways from upstream regulatory points that are blocked by cancer therapies. The mechanisms underlying these splicing changes range from stable alterations in gene sequence/structure to deregulation of splicing regulatory factors. In this review, the role of splice variants in cancer therapy resistance will be discussed, with examples of how mechanistic understanding of these processes has led to the development of novel strategies for therapy resensitization.
authors: Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota Twin Cities, Minneapolis, MN 55455, USA. dehm@umn.edu
authors: Scott M
authors: SM
authors: Dehm
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D014644:Genetic Variation / Q000235:genetics*; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D012326:RNA Splicing / Q000187:drug effects* / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins
references: PLoS Genet. 2011 Mar;7(3):e1001351
references: 21483803
references: Trends Genet. 2011 May;27(5):196-205
references: 21497936
references: Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22
references: 16672372
references: Cancer Res. 2007 Mar 1;67(5):2072-80
references: 17332336
references: Ann Oncol. 2006 Sep;17 Suppl 10:x315-24
references: 17018746
references: Genes Dev. 2010 Nov 1;24(21):2343-64
references: 21041405
references: Oncogene. 2013 Jun 6;32(23):2848-57
references: 22797067
references: Cancer Res. 2013 Jan 15;73(2):483-9
references: 23117885
references: Endocr Relat Cancer. 2011 Sep 20;18(5):R183-96
references: 21778211
references: Curr Genomics. 2007 May;8(3):163-70
references: 18645600
references: Nature. 2008 May 1;453(7191):110-4
references: 18408710
references: Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14907-12
references: 16997913
references: Cancer Res. 2011 Mar 15;71(6):2108-17
references: 21248069
references: Nat Struct Mol Biol. 2007 Mar;14(3):185-93
references: 17310252
references: Nat Struct Mol Biol. 2012 Jan 15;19(2):220-8
references: 22245967
references: Biochem Pharmacol. 2012 Apr 15;83(8):1063-72
references: 22248731
references: Cancer Res. 2009 May 15;69(10):4252-9
references: 19435898
references: Nature. 2012 Sep 6;489(7414):101-8
references: 22955620
references: Cancer Discov. 2011 Nov;1(6):524-38
references: 22145100
references: Nature. 2011 Nov 23;480(7377):387-90
references: 22113612
references: Nat Med. 2012 Mar 18;18(4):521-8
references: 22426421
references: Pharmacol Ther. 2012 Dec;136(3):283-94
references: 22909788
references: Clin Cancer Res. 2011 Jun 1;17(11):3716-26
references: 21512144
references: Blood. 2008 Nov 1;112(9):3847-55
references: 18650450
references: Mol Cell Biol. 2003 Aug;23(16):5692-705
references: 12897141
references: Cancer Res. 2012 Jul 15;72(14):3457-62
references: 22710436
references: Nat Rev Drug Discov. 2012 Nov;11(11):847-59
references: 23123942
references: Blood. 2009 Apr 30;113(18):4362-9
references: 19131550
references: Oncogene. 2012 Nov 8;31(45):4759-67
references: 22266865
references: Cancer Genet Cytogenet. 2006 Jan 1;164(1):39-43
references: 16364761